Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
Kmt2a
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "Kmt2a" in MCE Product Catalog:
2
2 Cited Publications
Synonyms: JNJ-75276617; Menin-MLL inhibitor 24
Target:
Áreas de investigación:
Bleximenib (JNJ-75276617) is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib can be used in the research of tumors such as leukemia [2].
2
2 Cited Publications
Synonyms: JNJ-75276617 oxalate; Menin-MLL inhibitor 24 oxalate
Target:
Áreas de investigación:
Bleximenib (JNJ-75276617) oxalate is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia [2].
Synonyms: DSP-5336
Target:
Áreas de investigación:
Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations [2] .
Referencia número: HY-172416
No. CAS: 2939850-17-4
Synonyms: ZE63-0302
Target:
Áreas de investigación:
Balomenib (ZE63-0302) is an orally bioavailable menin-KMT2A interaction inhibitor. Balomenib disrupts menin-KMT2A binding, reverses aberrant HOX gene expression. Balomenib inhibits Meis1 mRNA expression in KMT2A-rearranged acute myeloid leukemia cells. Balomenib can be used for the research of leukemia .
Referencia número: HY-RS07401
Target:
Áreas de investigación:
KMT2A Human Pre-designed siRNA Set A contains three designed siRNAs for KMT2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Referencia número: HY-RS18528
Target:
Áreas de investigación:
Kmt2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kmt2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Referencia número: HY-RS25010
Target:
Áreas de investigación:
Kmt2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Kmt2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Referencia número: HY-148669B
Pureza: 98.37%
Synonyms: (S)-JNJ-75276617 oxalate; (S)-Menin-MLL inhibitor 24 oxalate
Target:
Áreas de investigación:
(S)-Bleximenib (oxalate) is a S-Enantiomer of Bleximenib oxalate (HY-148669A). Bleximenib (JNJ-75276617) oxalate is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia .
Referencia número: HY-170832
Áreas de investigación:
Menin–KMT2A-IN-1 (Compound 20) is the inhibitor for menin–KMT2A that binds to menin with an IC50 of 8 nM, and inhibits the interaction between menin and lysine methyltransferase 2A (KMT2A). Menin–KMT2A-IN-1 inhibits hERG with an IC50 of 65 μM. Menin–KMT2A-IN-1 inhibits cell MV4-11 with an IC50 of 74 nM. Menin–KMT2A-IN-1 exhibits good pharmacokinetic characteristics in CD-1 mouse with an orally bioavailability of 74% .
Referencia número: HY-P85279
Synonyms: MLL; ALL1; CXXC7; HRX; HTRX; Kmt2a; MLL1; TRX1; Histone-lysine N-methyltransferase MLL; ALL-1; CXXC-type zinc finger protein 7; Lysine N-methyltransferase 2a; Kmt2a; Trithorax-like protein; Zinc finger protein HRX
Referencia número: HY-P85279A
Synonyms: MLL; ALL1; CXXC7; HRX; HTRX; Kmt2a; MLL1; TRX1; Histone-lysine N-methyltransferase MLL; ALL-1; CXXC-type zinc finger protein 7; Lysine N-methyltransferase 2a; Kmt2a; Trithorax-like protein; Zinc finger protein HRX
Referencia número: HY-P700485
Pureza: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: EPS15; AF1P; Epidermal Growth Factor Receptor Pathway Substrate 15; ALL1 Fused Gene From Chromosome 1; Epidermal Growth Factor Receptor Substrate 15; Protein Eps15; Protein AF-1p; Kmt2a Fusion; AF-1P; Kmt2a; MLLT5
Referencia número: HY-148829
No. CAS: 2407449-49-2
MS40 is a WDR5 PROTAC degrader (Kd = 125 nM). MS40 promotes the ubiquitination and degradation of WDR5. MS40-induced WDR5 degradation leads to the dissociation of the MLL/KMT2A complex from chromatin, resulting in decreased H3K4me2 levels. MS40 can be used in the study of primary leukemia .
Referencia número: HY-156794A
Synonyms: DSP-5336 enantiomer
Target:
Áreas de investigación:
Enzomenib enantiomer (DSP-5336 enantiomer) is an enantiomer of Enzomenib (HY-156794). Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations [2] .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
